AbCellera Biologics vs Enanta Pharmaceuticals
ABCL and ENTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABCL and ENTA compare
AbCellera Biologics is the larger company, worth 11 times as much as Enanta Pharmaceuticals ($3.5B against $320M).
Enanta Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −96.9% compared with −219% at AbCellera Biologics.
AbCellera Biologics scores higher on the StockData Score (8 against 2 for Enanta Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABCL | ENTA |
|---|---|---|
| Size and price | ||
| Market cap | $3.5B | $320M |
| Share price | $11.49 | $10.99 |
| Change, 1 year | 189% | −7.9% |
| Change, 5 years | −27.3% | −85.4% |
| Beta (5Y) | 1.46 | 1.14 |
| Employees | 562 | 120 |
| StockData Score | ||
| Total score | 8 (better) | 2 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 51.9× | 4.9× (better) |
| P/B | 3.3× | 3.2× (better) |
| FCF yield | −0.93% (better) | −11.5% |
| Fair value | $4.50 | $9.32 |
| Margin of safety | −155% | −17.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 92.1% | – |
| Revenue growth, 5Y average | −20.3% | −11.8% (better) |
| Profitability | ||
| Operating margin | −298% | −90.0% (better) |
| Net margin | −219% | −96.9% (better) |
| FCF margin | −48.4% (better) | −56.6% |
| Return on equity | −14.6% (better) | −70.1% |
| Return on invested capital | −41.7% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −4.5× |
| Current ratio | 12.43 (better) | 3.76 |
| Altman Z-score | 4.92 (better) | −0.97 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 37.9% | 93.6% |
| Held by insiders | 22.8% | 7.9% |
| Insider net buying, 12 months | $3.2M (better) | −$183K |
| Short interest, % of float | 12.3% | 6.9% |
Go deeper
- ABCL stock overview
- ABCL income statement
- ABCL valuation and score
- ENTA stock overview
- ENTA income statement
- ENTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.